84 related articles for article (PubMed ID: 22213308)
1. Analysis of failures in patients with FIGO stage IIIc1-IIIc2 endometrial cancer.
Gadducci A; Cosio S; Fabrini MG; Guerrieri ME; Greco C; Genazzani AR
Anticancer Res; 2012 Jan; 32(1):201-5. PubMed ID: 22213308
[TBL] [Abstract][Full Text] [Related]
2. An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma.
Liang LW; Perez AR; Cangemi NA; Zhou Q; Iasonos A; Abu-Rustum N; Alektiar KM; Makker V
Int J Gynecol Cancer; 2016 Mar; 26(3):497-504. PubMed ID: 26825840
[TBL] [Abstract][Full Text] [Related]
3. Impact of Lymph Node Ratio and Adjuvant Therapy in Node-Positive Endometrioid Endometrial Cancer.
Fleming ND; Soliman PT; Westin SN; dos Reis R; Munsell M; Klopp AH; Frumovitz M; Nick AM; Schmeler K; Ramirez PT
Int J Gynecol Cancer; 2015 Oct; 25(8):1437-44. PubMed ID: 26332387
[TBL] [Abstract][Full Text] [Related]
4. Effects of Adjuvant Radiation Plus Chemotherapy on Survival Outcomes in Stage III C Endometrial Cancer According to Histology: Analysis of Data from the Surveillance, Epidemiology, and End Results Database.
Kou J; Yan G; Xiao L; Wei N; Ren H; Xu J
Technol Cancer Res Treat; 2023; 22():15330338231208610. PubMed ID: 37926997
[No Abstract] [Full Text] [Related]
5. Treatment of node-positive endometrial cancer: chemotherapy, radiation, immunotherapy, and targeted therapy.
Tubridy EA; Taunk NK; Ko EM
Curr Treat Options Oncol; 2024 Mar; 25(3):330-345. PubMed ID: 38270800
[TBL] [Abstract][Full Text] [Related]
6. Comparing the survival rates of patients with stage IIIC endometrial cancer undergoing sandwich therapy to those undergoing sequential chemotherapy and radiotherapy: a meta-analysis.
Zhang MM; Chen YK; Shi L; Ma J; Jia JD; Zhao XW
Clin Transl Oncol; 2024 Jun; 26(6):1329-1337. PubMed ID: 38079088
[TBL] [Abstract][Full Text] [Related]
7. Effect of adjuvant treatment on survival in 2023 FIGO stage IIC endometrial cancer.
Akgor U
J Gynecol Oncol; 2024 May; 35(3):e89. PubMed ID: 38606829
[No Abstract] [Full Text] [Related]
8. Risk Factors for Nodal Failure in Patients with FIGO IIIC Cervical Cancer Receiving Definitive Image-Guided Radiotherapy.
Liu X; Hou X; Hu K; Zhang F; Wang W; Ren K
Curr Oncol; 2023 Dec; 30(12):10385-10395. PubMed ID: 38132390
[TBL] [Abstract][Full Text] [Related]
9. Prognostic performance of the 2023 FIGO staging schema for endometrial cancer.
Matsuo K; Chen L; Klar M; Lee MW; Machida H; Mikami M; Muderspach LI; Carlson JW; Roman LD; Wright JD
Gynecol Oncol; 2024 May; 187():37-45. PubMed ID: 38713997
[TBL] [Abstract][Full Text] [Related]
10. Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters.
Versluis MA; de Jong RA; Plat A; Bosse T; Smit VT; Mackay H; Powell M; Leary A; Mileshkin L; Kitchener HC; Crosbie EJ; Edmondson RJ; Creutzberg CL; Hollema H; Daemen T; de Bock GH; Nijman HW
Br J Cancer; 2015 Sep; 113(5):786-93. PubMed ID: 26217922
[TBL] [Abstract][Full Text] [Related]
11. Author's reply to: Effect of adjuvant treatment on survival in 2023 FIGO stage IIC endometrial cancer.
Lee YY; Chen YL; Lai YL
J Gynecol Oncol; 2024 May; 35(3):e88. PubMed ID: 38606828
[No Abstract] [Full Text] [Related]
12. Response to: Author's reply to: Effect of adjuvant treatment on survival in 2023 FIGO stage IIC endometrial cancer.
Akgor U; Ozgul N; Ayhan A
J Gynecol Oncol; 2024 May; 35(3):e92. PubMed ID: 38616118
[No Abstract] [Full Text] [Related]
13. Improving outcomes for older women with gynaecological malignancies.
Dumas L; Ring A; Butler J; Kalsi T; Harari D; Banerjee S
Cancer Treat Rev; 2016 Nov; 50():99-108. PubMed ID: 27664393
[TBL] [Abstract][Full Text] [Related]
14. [Prevention and treatment of endometrial cancer].
Kong BH; Song K; Yin AJ
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(10):715-720. PubMed ID: 38462350
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Racial Disparities on Outcome in Patients With Stage IIIC Endometrial Carcinoma: A Pooled Data Analysis: Erratum.
Am J Clin Oncol; 2023 Jun; 46(6):279. PubMed ID: 37022014
[No Abstract] [Full Text] [Related]
16. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.
Milgrom SA; Kollmeier MA; Abu-Rustum NR; Tew WP; Sonoda Y; Barakat RR; Alektiar KM
Gynecol Oncol; 2013 Sep; 130(3):436-40. PubMed ID: 23800696
[TBL] [Abstract][Full Text] [Related]
17. Analysis of patients with stage IIIC endometrial cancer.
Turan T; Ureyen I; Duzguner I; Ozkaya E; Tasci T; Karalok A; Boran N; Kose MF; Tulunay G
Int J Gynecol Cancer; 2014 Jul; 24(6):1033-41. PubMed ID: 24905617
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes and patterns of failure in women with stage IIIC
Lee JK; Mahan M; Hanna RK; Elshaikh MA
Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():192-197. PubMed ID: 28800504
[TBL] [Abstract][Full Text] [Related]
19. Stage IIIC endometrial cancer review: Current controversies in adjuvant therapy.
Buras AL; Mallen A; Wenham R; Montejo M
Gynecol Oncol Rep; 2021 May; 36():100754. PubMed ID: 33869712
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
